AstraNu

Integrated optical-coherence-tomography (OCT) hardware for medical-device makers, starting with ear and eye care.

Website: https://www.astranu.com/

Cover Block

Publicly reported

AstraNu comes into view first as a Bell Labs spinout trying to compress a known imaging modality into something device makers can actually embed. The public record is still thin, but the company’s positioning is consistent across launch, investor, and state-level coverage: integrated optical-coherence-tomography hardware for medical-device manufacturers, with an initial emphasis on ear and eye care [Nokia, May 2025] [ROI-NJ, October 2026] [PRNewswire, Nov 2026].

Field Value
Name AstraNu
Tagline Integrated optical-coherence-tomography (OCT) hardware for medical-device makers, starting with ear and eye care
Headquarters New Providence, New Jersey, US [LinkedIn, retrieved 2026]
Founded 2025 [Nokia, May 2025]
Stage Seed [PRNewswire, Nov 2026]
Business model Hardware + Software
Industry Healthtech
Technology Hardware
Geography North America
Growth profile Venture Scale
Founding team Corporate Spinout [Nokia, May 2025]
Funding label Seed [PRNewswire, Nov 2026]
Total disclosed ~$3,500,000 [PRNewswire, Nov 2026]

Links

Publicly reported

Summary and Signal

PUBLIC AstraNu is a 2025 Nokia Bell Labs spinout building chip-scale optical coherence tomography hardware for medical-device manufacturers, and it warrants attention because it is trying to compress a clinically useful imaging stack into an OEM-ready module at a point when medtech buyers still face cost, size, and integration constraints in ear and eye care devices [Nokia, May 2025] [ROI-NJ, October 2026]. The founding story matters here: Nokia and Celesta Capital launched the company to commercialize Bell Labs imaging technology, with an initial healthcare emphasis rather than a broad industrial rollout [Nokia, May 2025] [Converge Digest, May 2025].

The core product is an integrated OCT "engine module" that medical-device makers can embed in their own products, and public reporting describes the module as combining the required optical components onto a single chip and being 10x smaller and cheaper than traditional components [ROI-NJ, October 2026]. If that form factor and cost claim holds in production, the practical implication is not just better imaging performance, but a wider set of device categories that can plausibly absorb OCT without the footprint and bill-of-material burden of conventional architectures [ROI-NJ, October 2026] [Converge Digest, May 2025].

The team has technical credibility anchored in the originating lab: CEO Trevor Hawkins is described by Nokia as a healthcare-technology executive with decades of startup scaling experience, while Michael Eggleston and Bibek Samanta are identified as Bell Labs co-inventors of the integrated OCT technology [Nokia, May 2025]. Public materials also place Eggleston in a continuing technical leadership role at AstraNu, which is useful context for investors evaluating whether the spinout retained enough of the underlying invention talent to move from lab asset to manufacturable product [LinkedIn, retrieved 2026] [Nokia, May 2025].

On funding, AstraNu disclosed a $3.5 million seed round in November 2026 led by Celesta Capital, with co-investment from the New Jersey Innovation Evergreen Fund, and NJEDA separately reported approval of up to $1.5 million through that program [PRNewswire, Nov 2026] [NJEDA, October 2026]. The business model is straightforward on paper, hardware plus software sold into medical-device OEMs, but the next 12 to 18 months will likely turn on evidence that the company can translate Bell Labs provenance into design wins, regulatory pathway clarity, and repeatable productization rather than remaining a technically promising component story [PRNewswire, Nov 2026] [LinkedIn, retrieved 2026].

One source, partially checked -- This section relies on one independent news source for product specifics, one official launch announcement, and company or platform profiles for business model context.

Taxonomy Snapshot

Axis Value
Stage Seed
Business Model Hardware + Software
Industry / Vertical Healthtech
Technology Type Hardware
Geography North America
Growth Profile Venture Scale
Founding Team Corporate Spinout
Funding Seed, total disclosed ~$3,500,000

Company Overview

PUBLIC

AstraNu enters the record as a Bell Labs spinout with a fairly narrow initial brief: package optical-coherence-tomography hardware into a form factor medical-device makers can actually integrate [astranu.com, retrieved 2026] [Crunchbase, retrieved 2026]. Public company materials place the business in New Providence, New Jersey, and Crunchbase lists a 2025 founding date, which fits the timing of its first appearance as a standalone company in public databases [astranu.com, retrieved 2026] [Crunchbase, retrieved 2026].

The company website describes AstraNu as an integrated photonics company applying telecom-derived components and know-how to healthcare imaging, while also referencing broader uses beyond healthcare [astranu.com, retrieved 2026]. That matters because the legal and commercial identity looks early but coherent: a venture-backed spinout, headquartered in New Jersey, with a defined first market rather than a general-purpose photonics platform presented without a go-to-market frame [astranu.com, retrieved 2026] [Crunchbase, retrieved 2026].

Public milestones are still sparse, which is typical at this age, but the chronology is straightforward. Crunchbase records AstraNu as founded in 2025, and the company had a Crunchbase-listed seed financing by 2026; the website by retrieval in 2026 presents the company as active and focused on integrated OCT for medical devices [Crunchbase, retrieved 2026] [astranu.com, retrieved 2026]. On the evidence available from the permitted sources for this section, that leaves AstraNu as a newly formed New Jersey healthtech hardware company with an identifiable origin, disclosed headquarters, and a short but internally consistent public timeline [Crunchbase, retrieved 2026] [astranu.com, retrieved 2026].

Well sourced -- Confirmed by Crunchbase and the company website.

The Product and the Stack

Public record plus analysis

AstraNu is selling a component rather than a finished clinical device, and that distinction matters for how the product should be read. Public materials describe the company’s core offer as an integrated Optical Coherence Tomography, or OCT, engine module that medical-device manufacturers can embed into their own systems [ROI-NJ, October 2026]. AstraNu says the platform applies telecom industry materials, components, and know-how to healthcare imaging, reflecting its Bell Labs origin, while LinkedIn and other company profiles describe the broader technology as integrated photonics and low-cost, high-performance 4D imaging for next-generation medical devices [astranu.com, retrieved 2026] [LinkedIn, retrieved 2026] [RocketReach, retrieved 2026].

The technical claim that stands out is miniaturization at the optical-component level. ROI-NJ reported that AstraNu’s engine module combines the required optical components onto a single chip and is described as "10x smaller and cheaper than traditional components," a statement that, if borne out in customer integration work, would speak directly to bill of materials, form factor, and OEM adoption friction [ROI-NJ, October 2026]. The same public reporting and launch coverage position the initial clinical use case in non-invasive imaging for hearing and middle-ear conditions, with the stated aim of improving diagnosis and reducing reliance on CT, MRI, or exploratory surgery in certain workflows [Converge Digest, May 2025].

The product surface beyond that first wedge is plausible, but still lightly evidenced in public. AstraNu has also pointed to ear and eye care more broadly, and its LinkedIn materials mention possible applications outside healthcare, including industrial metrology and FMCW LiDAR, though those look more like platform-adjacency claims than disclosed commercial programs at this stage [LinkedIn, retrieved 2026]. On the operating side, a January 2026 Lead Hardware Engineer posting in New Providence suggests active in-house hardware development and an early team structure, including language indicating the role could act as the sole electrical engineer, but any deeper view of the stack would be a technology-stack inference rather than disclosed product detail (inferred from job postings) [LinkedIn, January 2026].

One source, partially checked -- Product form factor and use case are supported by ROI-NJ and Converge Digest, while several broader technology descriptions remain company- or profile-sourced.

The Market They Are Entering

PUBLIC

The market matters now because AstraNu sits at the intersection of two durable buyer pressures, medical devices that need better point-of-care imaging and component platforms that lower size and cost without asking OEMs to rebuild their product stack from scratch [Nokia, May 2025] [ROI-NJ, October 2026].

Public source coverage on AstraNu does not provide a cited TAM, SAM, or SOM, and no named third-party market report appears in the supplied research. The cleaner way to frame the addressable market, based on public evidence, is through the problem definition rather than unsupported sizing: AstraNu is targeting medical-device manufacturers with an integrated OCT engine module for embedded use in ear- and eye-care products, beginning with non-invasive imaging for hearing and middle-ear conditions [ROI-NJ, October 2026] [Converge Digest, May 2025]. That positioning suggests an initial wedge inside the broader medical imaging components market, with expansion potential into other device categories if the module proves clinically useful and manufacturable at scale, but the public record here does not support a numeric demand model.

Demand drivers are easier to see than market size. Nokia's launch statement and Converge Digest's coverage both emphasize non-invasive imaging and clinical workflows that could reduce misdiagnosis while lowering dependence on CT, MRI, or exploratory surgery in selected use cases [Nokia, May 2025] [Converge Digest, May 2025]. ROI-NJ adds the commercial angle: a plug-in OCT engine that is described as 10x smaller and cheaper than traditional components would matter to OEM buyers only if it simplifies integration economics, shortens development cycles, or enables form factors that incumbent optical assemblies cannot support [ROI-NJ, October 2026]. In other words, the demand case is not abstract imaging growth, it is whether a device maker can ship a better product with a smaller bill of materials and less design friction.

The adjacent markets in the public materials are broad enough to be notable, but still secondary to the healthcare thesis. AstraNu's LinkedIn profile and website describe applications beyond healthcare, including industrial metrology and FMCW LiDAR, and note that the platform applies telecom materials, know-how, and components to healthcare imaging [LinkedIn, retrieved 2026] [astranu.com, retrieved 2026]. That is strategically interesting because it points to a component architecture that may travel across sectors, but the evidence does not yet show commercial traction outside medical devices, so those adjacencies read as option value rather than a current market base.

Regulatory and macro forces cut both ways. On the favorable side, healthcare systems generally reward tools that can improve diagnostic accuracy with less invasive workflows, and AstraNu's early messaging is aligned with that clinical and economic logic [Converge Digest, May 2025]. On the constraining side, any supplier selling into regulated medical-device programs typically faces long design cycles, validation demands, and dependence on OEM adoption timetables, which means even a technically elegant component can take time to convert into production revenue. The Bell Labs spinout origin helps explain why the company is pursuing an enabling-technology position rather than a direct-to-provider model, but it also implies that market capture will likely depend on partner design wins, not broad top-down category adoption alone [Nokia, May 2025].

Market lens Public evidence Implication for AstraNu
Initial target market Embedded imaging modules for medical-device manufacturers, starting with ear and eye care [ROI-NJ, October 2026] [Converge Digest, May 2025] Narrower initial wedge than "medical imaging" broadly, which can help focus productization and regulatory strategy
Demand driver Potential for non-invasive imaging that may reduce misdiagnosis and reliance on CT, MRI, or exploratory surgery in some use cases [Converge Digest, May 2025] Clinical utility must be clear enough to justify OEM integration effort
Economic driver Engine module described as 10x smaller and cheaper than traditional components [ROI-NJ, October 2026] If borne out in production, size and cost could be the strongest procurement lever
Adjacent markets Industrial metrology and FMCW LiDAR cited in company materials [LinkedIn, retrieved 2026] [astranu.com, retrieved 2026] Adjacent sectors expand the strategic surface area, but remain unproven commercially

The table makes the main point plainly: the public market case is specific rather than expansive. AstraNu appears to be pursuing a component-level wedge where integration economics and clinical usefulness matter more than headline imaging market size.

No independent source found -- This section relies mainly on company materials and launch or regional coverage, with no cited third-party market sizing report in the supplied research.

The Competitive Field

MIXED AstraNu is not entering imaging as a stand-alone device company, but as a component supplier that asks medical-device manufacturers to swap bulkier OCT subsystems for a chip-scale engine, which puts it in a different lane from both diagnostic incumbents and broad photonics platforms [ROI-NJ, October 2026] [Nokia, May 2025].

On the public record, the competitive map is clearer by category than by named company. At the clinical end, AstraNu is pushing into ear and eye care workflows where existing diagnostic pathways can include CT, MRI, or exploratory procedures, and where device makers already have established hardware stacks and regulatory habits [Converge Digest, May 2025]. Those modalities are substitutes rather than direct product peers, but they matter because they set the adoption threshold: an OEM has to believe a plug-in OCT engine improves cost, size, and workflow enough to justify redesign [ROI-NJ, October 2026].

The next layer of competition is upstream. Nokia and Converge Digest both describe AstraNu as a Bell Labs spinout built around integrated OCT, while ROI-NJ describes the product as an engine module for medical-device manufacturers, which implies the immediate contest is with conventional discrete optical-component architectures and incumbent supplier relationships rather than with a single named startup selling the same module today [Nokia, May 2025] [Converge Digest, May 2025] [ROI-NJ, October 2026]. Adjacent substitutes also matter: AstraNu's own materials reference industrial metrology and FMCW LiDAR, but the company has publicly emphasized healthcare first, suggesting management is narrowing the battlefield rather than trying to win several photonics markets at once [LinkedIn, retrieved 2026] [astranu.com, retrieved 2026].

Where AstraNu appears strongest today is in technical origin and form factor. The company can point to Bell Labs provenance, named co-inventors Michael Eggleston and Bibek Samanta, and a launch structure backed by Celesta Capital, which gives it more credibility with sophisticated OEM buyers than a first-time imaging startup would usually have at seed [Nokia, May 2025] [PRNewswire, Nov 2026]. The quoted claim that the engine is 10x smaller and cheaper than traditional components is strategically important if it holds in production, because size and bill-of-materials reductions are legible to device makers in a way that broad platform claims are not [ROI-NJ, October 2026]. That edge is still perishable. Until AstraNu converts technical differentiation into design wins, manufacturing proof, and regulatory integration inside customer products, Bell Labs pedigree is a door-opener rather than a moat [Nokia, May 2025] [PRNewswire, Nov 2026].

The main exposure is commercial, not scientific. Public sources do not identify named customers, completed deployments, or signed medical-device partnerships, which leaves AstraNu exposed to larger incumbent suppliers and established OEM internal teams that already control purchasing channels and product roadmaps [Nokia, May 2025] [PRNewswire, Nov 2026]. Nokia is the clearest named actor around the company, but as originator rather than an operating competitor in this context; that distinction matters because AstraNu still needs independent go-to-market traction beyond the spinout story [Nokia, May 2025]. Over the next 18 months, the most plausible competitive scenario is that established medical-device manufacturers remain the practical winners if procurement cycles stay conservative and product redesign timelines slip. AstraNu is the most plausible winner if the company can show that the chip-scale module reduces integration cost and size without adding regulatory friction, because that would shift the buying debate from experimental imaging to component economics [ROI-NJ, October 2026] [Converge Digest, May 2025].

One source, partially checked -- Competitive framing is grounded in Nokia, ROI-NJ, Converge Digest, LinkedIn, and the company website, but named direct competitors are not confirmed in the source set and several positioning claims remain company-originated.

Opportunity

Upside case

PUBLIC The prize here is not a better standalone imaging tool, but a chance to become the embedded OCT engine that medical-device makers standardize on when they want high-resolution imaging without the size and cost penalty of legacy optical assemblies [ROI-NJ, October 2026] [Nokia, May 2025].

The cleanest upside case is that AstraNu becomes the component layer that sits inside a new class of ear- and eye-care devices, rather than trying to sell finished systems into clinics one account at a time [ROI-NJ, October 2026]. That matters because the company is positioned as a supplier to medical-device manufacturers, its core product is described as an integrated OCT engine module, and the technical claim that the module combines optical components onto a single chip points to OEM embedment as the natural commercialization route [ROI-NJ, October 2026] [Converge Digest, May 2025]. If that architecture works in production, the path to scale is more reachable than a de novo medtech go-to-market: one design win can propagate across many end users through a partner's installed base.

The evidence is still early, but it is directionally supportive. AstraNu came out of Nokia Bell Labs with named co-inventors tied to the underlying integrated OCT work, and Celesta Capital backed the spinout at launch and then led the disclosed $3.5 million seed round in November 2026 [Nokia, May 2025] [PRNewswire, Nov 2026]. Public materials also keep repeating the same commercial promise, smaller, cheaper, non-invasive imaging for medical-device integration, which at least shows message discipline around one wedge rather than a scattered set of product bets [Converge Digest, May 2025] [ROI-NJ, October 2026].

Scenario paths

PUBLIC The upside branches into a few distinct paths, and each depends on a different kind of proof point.

Scenario What happens Catalyst Why it's plausible
Middle-ear OEM standard AstraNu's chip-scale OCT engine becomes a preferred imaging module for device makers building tools for hearing and middle-ear diagnosis A first disclosed OEM integration or development partnership in ear-care hardware The company publicly identifies non-invasive imaging for hearing and middle-ear conditions as its initial clinical application, and positions the product as an engine module for device manufacturers [Converge Digest, May 2025] [ROI-NJ, October 2026]
Expand from ear care into eye care AstraNu uses the same core integrated photonics platform to move from one clinical wedge into adjacent ophthalmic devices Product validation in the first clinical wedge plus a partner seeking the same size and cost advantages in eye-care hardware The public summary and company positioning describe ear and eye care as initial focus areas, suggesting a platform with more than one medical endpoint if integration claims hold [Nokia, May 2025] [astranu.com]
Cross-vertical photonics platform Healthcare funds the initial commercialization, then the core integrated photonics stack is adapted for industrial metrology or FMCW LiDAR Evidence that the integrated platform performs reliably outside the first medical-device use case AstraNu and related public profiles describe applications beyond healthcare, including industrial metrology and FMCW LiDAR, which widens the eventual surface area if the base engine proves manufacturable [LinkedIn] [astranu.com]

The table reads as possibility, not visibility. No public source in hand names a commercial customer, a completed device deployment, or a signed manufacturer partnership, so the catalysts above remain the gating items rather than boxes already checked [MobiHealthNews] [Nokia, May 2025].

How scale could compound

PUBLIC If AstraNu works, the compounding mechanism is design-in lock-in rather than consumer brand pull.

Medical-device components that save space, consolidate parts, and lower bill-of-materials cost can become sticky once an OEM engineers them into a product line, especially when the underlying function is core to diagnosis or imaging performance. AstraNu's public pitch, a single-chip OCT engine that is described as 10x smaller and cheaper than traditional components, is the kind of claim that could create this lock-in because it speaks to both product form factor and economics, not just image quality [ROI-NJ, October 2026]. In that model, each successful integration does three jobs at once: it validates manufacturability, shortens the next OEM sales cycle, and increases the practical cost of switching away.

There is an early hint of that operating model in how the company is hiring. A January 2026 posting for a Lead Hardware Engineer in New Providence described AstraNu as a seed-stage integrated-photonics startup and suggested a small, build-heavy team, consistent with a company trying to industrialize a core module rather than staff a broad clinical sales motion [LinkedIn, January 2026]. The Bell Labs origin also matters here, because the technical founders are tied to the invention and incubation of the integrated OCT technology itself, which can matter in debugging performance, packaging, and cost reduction through successive iterations [Nokia, May 2025].

What the upside could be worth

PUBLIC The size of the win is hard to anchor cleanly from public data because no credible market-size figure or close public comparable appears in the supplied record, but the structure of the opportunity still supports an ambitious outcome if OEM adoption arrives.

In the strongest public scenario, AstraNu would not be valued as a single-application hardware startup, but as a photonics platform with one proven healthcare wedge and credible adjacency into other imaging markets [astranu.com] [LinkedIn]. That would imply a much larger outcome than the current seed financing suggests, particularly because the company is trying to sit at the enabling-technology layer inside other manufacturers' products [PRNewswire, Nov 2026] [ROI-NJ, October 2026]. Any specific valuation figure here would go beyond the evidence in hand, so the more defensible framing is qualitative: if the company secures repeatable OEM design wins in ear care, extends into eye care, and shows the same chip-scale architecture travels into adjacent sensing markets, the result could be platform-scale enterprise value (scenario, not a forecast).

One source, partially checked -- This section relies on one independent local-news source for product configuration and cost-size claims, one corporate launch announcement for spinout and team details, one financing announcement for round confirmation, and company-controlled profiles for adjacency claims [ROI-NJ, October 2026] [Nokia, May 2025] [PRNewswire, Nov 2026] [astranu.com] [LinkedIn].

Sources

Publicly reported

  1. [Nokia, May 2025] Nokia and Celesta Capital launch Astranu to advance healthcare imaging technology | https://www.nokia.com/about-us/news/releases/2025/05/15/nokia-and-celesta-capital-launch-astranu-to-advance-healthcare-imaging-technology/

  2. [ROI-NJ, October 2026] New Jersey Economic Development Authority invests $16.5M to support 8 startups | https://www.roi-nj.com/2026/10/19/politics/new-jersey-economic-development-authority-invests-16-5m-to-support-8-startups/

  3. [PRNewswire, Nov 2026] AstraNu Closes $3.5 Million Seed Round Led by Celesta Capital to Commercialize Chip-Scale Optical Imaging Engine | https://www.prnewswire.com/news-releases/astranu-closes-3-5-million-seed-round-led-by-celesta-capital-to-commercialize-chip-scale-optical-imaging-engine-302941615.html

  4. [LinkedIn, retrieved 2026] Astranu | https://www.linkedin.com/company/astranu

  5. [Converge Digest, May 2025] Nokia and Celesta Capital Spin Out Astranu to Pioneer 3D Imaging | https://convergedigest.com/nokia-and-celesta-capital-spin-out-astranu-to-pioneer-3d-imaging

  6. [Crunchbase, retrieved 2026] Astranu - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/astranu

  7. [astranu.com, retrieved 2026] Astranu | https://www.astranu.com/

  8. [RocketReach, retrieved 2026] AstraNu | https://rocketreach.co/astranu-profile_b5c6c0f4f42e0f9d

  9. [NJEDA, October 2026] NJEDA Invests $16.5M to Support 8 Innovative NJ Startups | https://www.njeda.gov/njeda-invests-16-5m-to-support-8-innovative-nj-startups/

  10. [MobiHealthNews, retrieved 2026] Exclusive: AstraNu raises $3.5M for chip-scale optical imaging technology | https://www.mobihealthnews.com/news/exclusive-astranu-raises-35m-chip-scale-optical-imaging-technology

Articles about AstraNu

View on Startuply.vc